You are here » Home » Companies » Company Overview » Organon (India) Ltd

Organon (India) Ltd.

BSE: 532002 Sector: Health care
NSE: INFARINDIA ISIN Code: INE568A01018
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty

Organon (India) Ltd. (INFARINDIA) - Company History

Infar (India), a 50.43% subsidiary of AKZO Nobel Pharma, Netherlands, is a market leader in female healthcare and growth hormones. Nearly 80% of its sales come from pharmaceutical formulations (injectables and tablets). The remaining come from contraceptives and AIDS test units. Infar has a subsidiary -- Intercare, which manufactures general purpose and veterinary drugs which was amalgamated with the company from Oct.'00. Infar has obtained the marketing licence from Solvay Duphar, Holland, to manufacture Eldicet, the first selective calcium antagonist marketed in India. Nutricia, a Dutch company, has also granted Infar the permission to import and market the clinically nutritious products, Pepti 2000 and Bonvit. During 1996-97 it has allotted bonus shares to the existing shareholders in the ratio of 3 shares for every 5 shares held. The company has taken up a project for construction of pharamaceutical factory at Ganganagar, West Bengal for which land has already been acquired, the state-of-the-art factory would be built to international standards and this would lead to substantially expanding the capacity and quality of products of the company. During the year 1999, Recagon, a recombinant FSH was introduced for the first time in India and considerable sum has been spent for its introduction and reach in local clinical trials as it represents a complete new technology. The company has acquired land in Village Unsani, Dist: Howrah on Kona Expressway for setting up of a state-of-the art manufacturing facility. Company has divested from veterinary business and similar withdrawals from areas where the company lacks necessary knowledge and strength or does not see a long-term opportunity are under consideration.The upgradation and adaption of new technology at Ganganagar factory under Diosynth Business was completed during 2000-01.